TowerBrook and CD&R Complete Acquisition of R1 RCM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 19 2024
0mins
Should l Buy ?
Source: Newsfilter
Acquisition Announcement: R1 RCM Inc. has been acquired by investment funds from TowerBrook Capital Partners and Clayton, Dubilier & Rice for $14.30 per share, totaling approximately $8.9 billion, leading to the cessation of R1's common stock trading on Nasdaq.
Leadership Change: Joe Flanagan has taken over as CEO of R1, succeeding Lee Rivas, and aims to enhance operational excellence and innovation in healthcare revenue management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
